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Pancreatic neuroendocrine tumors are a rare entity with an incidence between 2 per million to 5 per 100 000.
Association with pancreatitis (acute or chronic) is rare and is considered to be determined by the tumoral
obstruction of pancreatic ducts, but sometimes occurs without any apparent relationship between them.
Non-functional neuroendocrine pancreatic tumors are usually diagnosed when either very large or metastatic. Small
ones are occasionally diagnosed when imagery is performed for other diagnostic reasons. Intraoperative discovery
is even rarer and poses problems of differential diagnosis with other pancreatic tumors. Association with chronic
pancreatitis is rare and usually due to pancreatic duct obstruction by the tumor. We describe the case of a patient
with a small non-functioning neuroendocrine tumor in the pancreatic tail accidentally discovered during surgery for
delayed traumatic splenic rupture associated with chronic alcoholic pancreatitis. The tumor of 1.5cm size was well
differentiated and confined to the pancreas, and was resected by a distal splenopancreatectomy.
Conclusions: Surgeons should be well aware of the rare possibility of a non-functional neuroendocrine tumor in
the pancreas, associated with chronic pancreatitis, surgical resection being the optimal treatment for cure.
Histopathology is of utmost importance to establish the correct diagnosis, grade of differentiation, malignancy
and prognosis.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2114470176676003.
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Pancreatic neuroendocrine tumors are a rare entity, part
of a larger group called gastroenteropancreatic endocrine
tumors, with histologic origins in the neuroendocrine cells
inside the pancreas [1].
Incidence ranges from 1–2 cases per million individuals
[2] to 2.5–5 cases per 100000 [3] and it will probably grow
more due to availability of modern and powerful diagnos-
tic tools. Incidence in autopsies ranges between 1.6% and
10% [4].
Association with pancreatitis (acute or chronic) is rare
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reproduction in any medium, provided the orobstruction of pancreatic ducts, but sometimes occurs
without any apparent relationship between them [5].Case presentation
A 58 years old patient was admitted in our surgical de-
partment for faintness and dizziness after a fall from
standing occurring a week before. Known as a heavy alco-
hol consumer, he was frequently brought in hospital be-
cause of staggering in the streets. He denied any personal
medical or surgical antecedents and couldn't indicate any
family medical history. He worked as farmer all his life
and had a history of smoking around 20 cigarettes per day
for 10 years but stopped 8 years ago. Physical examination
was normal, laboratory data within normal range except-
ing a mild anemia. Abdominal ultrasonography diagnosed
a 100/25 mm subcapsular hematoma on the posterior sidetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Surlin et al. Diagnostic Pathology 2012, 7:132 Page 2 of 5
http://www.diagnosticpathology.org/content/7/1/132and a 10 mm thick fluid collection on the medial side of
the spleen. There was no free fluid, nor other lesion of
parenchymal viscera. The initial decision was for conser-
vative management, patient’s status improving in the fol-
lowing days. Third day after admission, the patient
presented diffuse abdominal pain, cold sweats, tachycardia
over 100/min and falling blood pressure. There was a
strong suspicion of delayed splenic rupture and the patient
was immediately taken to operating room.
At laparotomy there were free fresh and old blood clots
in the peritoneal cavity and around the spleen, in quantity
estimated up to 700–800 ml and a ruptured subcapsular
hematoma on the posterior side of the spleen with active
bleeding from an irregular-shaped mid-splenic fracture of
3 cm depth. No other lesions were found. Dissection of
splenic vessels for vascular control, revealed a chronic
pancreatitis with peripancreatic fibrosis and a a 1.5-2 cm
tumor palpated in the pancreatic tail right in front of the
splenic hilum. The tumor had a slightly more consistency
than the pancreas. There were no enlarged lymphnodes
around in this area. A splenopancreatectomy was decided
then with a margin of at least 3 cm proximally. The pa-
tient had an uneventful postoperative course.
Gross and microscopic examination revealed, in the
pancreatic fragment attached to the spleen, a 1.5 cm
nodular, well circumscribed, firm, grayish tumor, unhomo-
genous, with hemmorhagic foci on section.
Microscopic examination revealed a tumor incompletely
delineated by a thin fibrous capsule (see Figure 1a).
Tumor cells presented a pattern predominantly pseudo-
glandular, consisting of polygonal cells with moderate eo-
sinophilic cytoplasm and round-oval nuclei with relatively
uniform shape and size (see Figure 1b). Small hemorrhagic
foci were observed in the tumor (see Figure 1c). There
was no vascular or perineural invasion, nor necrosis.
Number of mitosis observed was low: 2–3 mitosis /10
high power fields (400x).Figure 1 Histological profile of the studied tumor.Figure 1 - (a) Neuroendocrine pancreatic tumor (adeno-
carcinoma) well delineated by a pseudocapsule,
hematoxylin eosin (100x); (b) - Pseudoglandular pattern,
hematoxylin eosin (200x); (c) - Haemmorhagic foci and
variable fibro-collagen stroma, hematoxylin eosin (100x).
Immunohistochemical stainings revealed tumor cells
positive for chromogranin, synaptophysin, and neuron
specific enolase (see Figure 2a, 2b, 2c). Proliferation mar-
kers as MIB-1 (directed against the Ki-67 antigen), were
expressed in less than 2% of the tumor cells nuclei (see
Figure 2d).
Figure 2 - (a) Intense and diffuse immunostaining of the
tumor cells cytoplasm for Chromogranin, LSAB technique
(400x); (b) – Diffuse immunostaining of the tumor cells
cytoplasm for Synaptophysin, LSAB technique (200x); (c)
– Immunostaining of the tumor cells cytoplasm for NSE,
LSAB technique (200x); (d) - Rare Ki-67 positive neoplas-
tic cells, LSAB technique, (400x).
Based on those characteristics (proliferating tumor con-
fined to the pancreatic tissue, reduced size, and low prolif-
eration index, absence of necrosis, no vascular or
perineural invasion) the tumor was diagnosed as well dif-
ferentiated with benign behavior according to the WHO
classification [6]. 8 lymph nodes were examined and, apart
from the presence of different degrees of histiocytosis, no
tumoral involvement was found.
Discussion
Generally there are two categories of pancreatic neuroen-
docrine tumors: functional, releasing in the peripheral
blood active hormones responsible for a specific clinic
syndrome and non-functional, secreting either a function-
ally inert hormone or in very small amounts, therefore not
producing any clinical symptoms [7,8].
The proportion of non-functional tumors varies largely
in published series. A review by Ito et al. found 48% of
pancreatic neuroendocrine tumors as non-functional [9].
Figure 2 Immunohistochemical profile of the studied tumor.
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neuroendocrine tumors of pancreas found 71% of them
non-functional [10].
The peak incidence for these tumors is between 30 and
60 years of age [11]. Early clinical diagnosis of non-
functional pancreatic tumors is very rare because usually
they become symptomatic only when they grow larger or
metastasize. Otherwise they are discovered incidentally on
the occasion of imagistic tests performed for other med-
ical reasons. In our case, there is a very rare situation of
intraoperative discovery.
Abdominal ultrasound was performed before surgery
but, on regular examination, PNETs present a hypoechoic
aspect that cannot be differentiated from other types of
tumor, and could escape detection because of operator's
inexperience, flatulence, obesity, deep situations and loca-
tions in the tail [12]. In the case we describe the old and
organizing blood clots around the spleen surely contribu-
ted to hide the tumor.
Intraoperative discovery poses problems of diagnostic
and therapeutic decision. Association with a grossly aspect
of chronic pancreatitis raises the suspicion of pancreatic
cancer. Pancreatic neuroendocrine tumors represents
less than 3% from pancreatic tumors [13,14]. It is far
more rare than pancreatic adenocarcinoma, with a ratio
of 1:25 [6] being substantially rarer than adenocarcin-
omas and carrying a better prognosis [8]. Most neu-
roendocrine tumors of pancreas are located in the
pancreatic head [15]. In our case the tumor was located
near the splenic hilum.
In front of an accidentally discovered pancreatic tumor
we had to decide whether to perform or not a frozen bi-
opsy. Due to the fact that the tumor was well confined tothe pancreas and relatively easy amenable to resection,
there were no enlarged lymphnodes in the vicinity and the
pancreas presented a firm consistency, well suitable for su-
ture with low-risk for pancreatic fistula, a resection with
safe margins was decided.
We think that in such cases a frozen section could not
have brought any elements to change our decision. In
neuroendocrine tumors of pancreas the only reason to
perform a frozen section is when an enucleation is
planned but even in such situations there could be pro-
blems of differential diagnosis with papillary tumors [16].
The mainstay of treatment for neuroendocrine tumors
of pancreas is surgical resection. However, particularly for
non-functional tumors, it remains controversial as to
whether resection alters their natural history. Tumor enu-
cleation can be performed in cases in which the pancreatic
endocrine tumor is single, capsulated, of limited size (less
than 2 to 3 cm) and peripheral, situated at a distance from
the main duct [13,14]. The safe margin of resection is not
clearly indicated in the litterature. If the tumor is macro-
scopically well delimited the margin can be very narrow,
from few millimeters to 1 cm [16].
Immunohistochemistry is of outmost importance for
the study of neuroendocrine tumors of pancreas. Several
antibodies are available against neuroendocrine markers
such as NSE, CD56, synaptophysin, CgA, and other hor-
mones. It is important to discriminate well-differentiated
forms from poorly differentiated carcinomas using malig-
nancy markers [17]. The malignant or metastatic potential
of neuroendocrine pancreatic tumors can be estimated
using the tumor size, mitotic index, expression of KI-67
protein, vascular invasion, and perineural invasion
[18]. The proliferation marker MIB-1 (directed against
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prognosis [3].
Association with pancreatitis (acute or chronic) was
already reported in the literature. Mostly, there are reports
of acute pancreatitis generated by obstruction of the main
duct by the tumor [5,19,20]. In some of the cases the acute
pancreatitis became chronic. In other, there was no evi-
dent relationship between chronic pancreatitis and the
neuroendocrine tumor [5]. In 71% of the cases the tumor
was malignant [19].
In our case the association between chronic pancreatitis
and PNET seemed purely incidental because the pancrea-
titis involved grossly the entire pancreatic gland and the
tumor was located in the proximity of the splenic hilum.
In addition, the patient was a chronic alcohol consumer, a
well-known etiological factor for chronic pancreatitis.
There are very few studies in the literature searching a
common genetic pathway for chronic pancreatitis and
pancreatic neuroendocrine tumors. In an interesting com-
parative study in search for specific molecular markers,
Bloomstone et al. [21] compared them with different other
pancreatic diseases as chronic pancreatitis and pancreatic
adenocarcinomas. They found that ELOVL4 (a gene codif-
ing the protein for the elongation of very-long-chain fatty
acids 4-like, responsible for the biosynthesis of fatty acids)
and CALCR (gene responsible for calcitonine receptor)
were increased both in neuroendocrine tumors and
chronic pancreatitis.
Overall prognosis after resection is much better than of
other pancreatic tumors. In a review of 3851 cases, sur-
vival was 59.3% at 5 years and 37.7% at 10-years. Age,
grade, distant metastases, tumor functionality, and type of
resection were independent predictors of survival, mean-
while gender, race, socioeconomic status, tumor size,
nodal status, margins, adjuvant chemotherapy, and hos-
pital volume had no influence [22].
Beside association with chronic pancreatitis, there are
reports of a unique association between carcinoid tumors
and renal cell carcinoma in a mature cystic teratoma of a
horseshoe kidney. In this case the tumor presented also a
low grade of malignancy and differentiation as adenocar-
cinoma as in our case [23]. Primary renal carcinoid
tumors are morphologically and histologically similar to
those in other sited. The surgical resection is curative
and prognosis is good in the absence of metastasis but
long term follow-up is recommended because distant re-
currence may occur up to seven years postoperatively
[23].
Immunohistochemical markers may be related also with
prognosis beside their diagnostic role. Expression of NSE
and CD 56 was studied in renal cell carcinoma and was
correlated with prognosis. First of all, NSE marker was
exhibited by 48% of the renal cell carcinoma in a series of
152 cases. In the same series there was an 18% of CD56positive stain. Renal cell carcinomas that exhibited NSE
and/or CD56 had a poorer prognosis.[24].
Conclusions
Incidental introperative discovery of a neuroendocine
adenocarcinoma is a rare event that may arouse important
diagnostic issues and therapeutic decisions. Association
with chronic alcoholic pancreatitis is also rare and not
fully understood. Histopathology and particularly immu-
nohistochemical stains remain crucial for the diagnosis in
respect of malignancy and prognosis.
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